Penumbra Inc.
Penumbra Reports Strong Q3 2025 Financial Results with Revenue Increase
Summary
Penumbra, Inc. announced financial results for the third quarter of 2025, reporting a revenue increase of 17.8% to $354.7 million compared to the same period in 2024. The company saw a 21.5% growth in U.S. revenue and a 18.5% increase in U.S. Thrombectomy revenue. Net income for the quarter was $45.9 million, with an adjusted EBITDA of $66.7 million. The company also updated its full-year 2025 financial outlook, increasing its total revenue guidance to a range of $1,375 million to $1,380 million.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement